ACE and gout: Higher utilization rates (p < 0.0001) were also reported for beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, a reflection of higher comorbidity rates in the gout cohort [36].